Identification of the mapping-based voltage-derived parameter for accurate arrhythmia outcome prediction in patients undergoing first PVI

T. Huang (Luzern)1, R. Carmen (Karlsruhe)2, A. Gamer (Luzern)1, S. Hess (Luzern)1, F. Cuculi (Luzern)3, M. Eichenlaub (Freiburg im Breisgau)4, H. Lehrmann (Bad Krozingen)5, A. Loewe (Karlsruhe)6, D. Trenk (Bad Krozingen)7, D. Westermann (Freiburg im Breisgau)8, T. Arentz (Bad Krozingen)9, A. S. Jadidi (Luzern 16)10
1Cantonal Hospital of Lucerne Cardiology Luzern, Schweiz; 2Karlsruhe, Deutschland; 3Luzerner Kantonsspital Luzern, Schweiz; 4University Heart Center Freiburg-Bad Krozingen Cardiology Freiburg im Breisgau, Deutschland; 5Universitäts-Herzzentrum Freiburg / Bad Krozingen Klinik für Kardiologie und Angiologie II Bad Krozingen, Deutschland; 6Karlsruher Institut für Technologie (KIT) Institut für Biomedizinische Technik Karlsruhe, Deutschland; 7Universitäts-Herzzentrum Freiburg / Bad Krozingen Klinische Pharmakologie Bad Krozingen, Deutschland; 8Universitäts-Herzzentrum Freiburg - Bad Krozingen Innere Medizin III, Kardiologie und Angiologie Freiburg im Breisgau, Deutschland; 9Universitäts-Herzzentrum Freiburg / Bad Krozingen Rhythmologie Bad Krozingen, Deutschland; 10Luzerner Kantonsspital Herzzentrum Luzern, Schweiz

Purpose: The current study aims to identify the LA voltage marker with the highest predictive value with regard to arrhythmia recurrence in AF patients undergoing de-novo circumferential pulmonary vein isolation (CPVI). 

Methods: 278 patients (36% female, 55% persistent AF) undergoing de-novo CPVI were enrolled in the study. High-density electro-anatomical mapping was performed strictly under sinus rhythm (SR) to determine the following parameters GMV, LVA, left atrial volume (LAV). All three parameters were extracted and quantified using an AI-algorithm developed by Karlsruhe Institute of Technology. Arrhythmia recurrence included occurrence of AF, atrial flutter and atrial tachycardia at 6-, 12- and 24-month FU respectively.  

Results: Arrhythmia recurrence occurred in 48 (17.3%) patients within 12-month FU and in 83 patients (29.9%) within 24-month FU. Multivariate COX regression identified persistent AF and LVA at 1.0mV threshold (continuous variable) as the only two significant predictors for arrhythmia recurrence at both 12-month FU (Persistent AF: HR=2.11, p=0.027; LVA: HR=1.02, p=0.034) and 24-month FU (Persistent AF: HR=1.84, p=0.013; LVA: HR=1.02, p=0.003). C-statistics identified the cut-off thresholds of LVA of >1.5cm2 and >3.0cm2 for paroxysmal and persistent AF cohorts, respectively. As a result, LVA >1.5 cm in paroxysmal cohort was associated with significant difference in arrhythmia freedom rate at 12-month (97.8% vs. 87.6%, p=0.015) and marginally significant difference at 24-month (82.7% vs. 67.6%, p=0.051). LVA >3.0cm2 in persistent cohort was associated with significant difference in arrhythmia freedom rate at both 12-month (89.2% vs. 68.5%, p=0.008) and 24-month (72.5% vs. 43.2%, p=0.002).  

Conclusion: Persistent AF and LVA at 1.0mV bipolar threshold in sinus map are highly predictive of arrhythmia recurrence after CPVI, however, more robust predictive performance is observed in persistent cohorts.